{"id":"xtr004","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, XTR004 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"XTR004 is a small molecule targeting the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:08.739Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07439133","phase":"PHASE3","title":"Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR)","status":"RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2025-11-14","conditions":"Coronary Artery Disease(CAD)","enrollment":395},{"nctId":"NCT07187895","phase":"PHASE2","title":"Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis","status":"TERMINATED","sponsor":"Sinotau Pharmaceutical Group","startDate":"2024-12-19","conditions":"Myocardial Perfusion Imaging, Diagnostic Certainty, Stable Coronary Artery Disease","enrollment":17},{"nctId":"NCT05885841","phase":"PHASE2","title":"Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD","status":"COMPLETED","sponsor":"Sinotau Pharmaceutical Group","startDate":"2022-02-15","conditions":"Coronary Artery Disease (CAD)","enrollment":83},{"nctId":"NCT05195879","phase":"PHASE1","title":"A Study of XTR004 Radiotracer in Healthy Volunteers","status":"COMPLETED","sponsor":"Sinotau Pharmaceutical Group","startDate":"2021-03-23","conditions":"Coronary Artery Disease (CAD), Myocardial Ischemia","enrollment":10},{"nctId":"NCT04596527","phase":"EARLY_PHASE1","title":"18F-FMPP PET MPI in the Detection of Coronary Artery Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-09-15","conditions":"Coronary Disease","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Drug: 99mTechnicium Sestamibi","Procedure: Coronary angiography"],"phase":"phase_3","status":"active","brandName":"XTR004","genericName":"XTR004","companyName":"Sinotau Pharmaceutical Group","companyId":"sinotau-pharmaceutical-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"XTR004 is a small molecule targeting the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}